Skip navigation
Moody's considers downgrading PharmaNet
By The Associated Press | 31 Oct 2008 | 02:40 PM ET
Text Size

NEW YORK - Moody's Investors Service said Friday it will consider downgrading its debt rating on PharmaNet Development Group Inc., a drug development services company.

Moody's cited a high rate of contract cancellations and doubts about the Princeton, N.J.-based company's ability to favorably refinance $144 million in convertible notes.

Holders will be able to exercise options on the notes in August.

Moody's currently has a "B3," or non-investment "junk," rating on PharmaNet. About $45 million of rated debt is affected.

The company's stock rose 54 cents, or 37 percent, to $2 in afternoon trading.

Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis